Furthermore, since high serum ANGPT2 levels were recently shown to constitute a negative predictive and prognostic biomarker for immune checkpoint therapy in melanoma [45], specific, potentially functional SNPs in ANGPT2 and TEK genes might have prognostic relevance not only after standard therapy in HNSCC, but also after immunotherapy. This evidence concerns the gene ANGPT2 and head and neck squamous cell carcinoma.